The medications' effects on reducing healthcare utilization for obesity-related complications may provide long-term cost offsets ^37
Prime Therapeutics performed a study that did not demonstrate an offset in medical costs in non-Diabetic members within two years
Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
gastric ultrasound study provides the most robust evidence to date, examining 220 patients and finding retained gastric contents in 40% of semaglutide patients versus 3% of controls (adjusted odds ratio 36.97, 95% confidence interval 16.5499.32) [34]
Services include rapid diagnosis and treatment for urgent pregnancy concerns, fetal monitoring and ultrasound, and care for pregnancy-related or postpartum complications
